A purified form of recombinant growth hormone known as somatropin, rh-GH, is produced by either Escherichia coli or mammalian cells. The pituitary gland is where endogenous human growth hormone (hGH) is created. The structure of growth hormone was discovered in 1972 after it was originally isolated in 1956. Growth hormone (GH) was previously generated from human cadavers prior to 1985, but its usage was discontinued as a result of Creutzfeldt-Jakob virus infection. Somatropin has been given the go-ahead to treat adults with short bowel syndrome as well as growth hormone deficit (GHD), growth failure, or short stature, cachexia, and AIDS wasting. Limited short-term results suggest that somatropin use may reduce visceral adipose tissue; the drug has been explored for the treatment of HIV-associated adipose redistribution syndrome (HARS). There are numerous somatropin medications available, each with unique indications and dose guidelines. It is important to choose products carefully because they could not be interchangeable. The FDA initially authorized somatropin in 1987.